CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma

Xu, Leilei; Xia, Chao; Sheng, Fei; Sun, Qi; Xiong, Jie; Wang, Shoufeng

doi:10.1093/carcin/bgy017

Cited by 27 publications

(33 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It plays a critical role in regulating the physical cytokinesis [20]. CEP55 upregulation was previously reported to promote the migration and invasion of tumor cells and is related to the dismal prognosis for lung cancer [16], breast cancer [21], oral squamous cell carcinoma [22], cervical cancer [23], and osteosarcoma [24]. Such finding was consistent with our findings in liver cancer.…”

Section: Discussionsupporting

confidence: 91%

Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer

Yang

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. This study was performed to investigate the association of CEP55 expression with liver cancer and explore potential underlying mechanisms. Materials and Methods. Data obtained from The Cancer Genome Atlas (TCGA) was used to investigate CEP55 expression, its prognostic value, the potential mechanisms of its upregulation, CEP55-related pathways, and its biological functions in liver cancer. Data from Gene Expression Omnibus (GEO) and International Cancer Genome Consortium (ICGC) was used to validate survival analysis. The correlation between CEP55 and tumor-infiltrating immune cells (TIICs) in liver cancer was determined by using Tumor Immune Estimation Resource (TIMER). Results. CEP55 was significantly overexpressed in the liver tumor sample compared to the adjacent normal liver sample. High CEP55 expression was significantly associated with histological grade, advanced stages, histological type, high T classification, and survival status. High CEP55 expression was significantly related to dismal prognosis compared with low CEP55 expression, which was validated by the GSE54236 dataset and ICGC database. Meanwhile, CEP55 was identified as the risk factor to independently predict overall survival (OS) for patients with liver cancer upon multivariate analysis. Enrichment analysis indicated that cell cycle, DNA replication, pathways in cancer, mTOR signaling pathway, and VEGF signaling pathway were significantly enriched in the high CEP55 expression group. In addition, the CEP55 expression was significantly related to the infiltration level of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells in hepatocellular carcinoma (HCC). CEP55 methylation level was negatively correlated to its mRNA expression. And patients with CEP55 hypermethylation and low expression can achieve a better prognosis than those with CEP55 hypomethylation and high expression. Conclusion. CEP55 may serve as a candidate treatment target for it is a determinant of prognosis and immune infiltration in liver cancer patients. DNA hypomethylation might contribute to the overexpression of CEP55 in liver cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer

Yang

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Furthermore, CEP55 promotes proliferation and invasion in osteosarcoma by regulating the AKT signaling pathway. In another study, data showed that CEPP55 facilitates the EMT process in renal cells and participates in the AKT pathway [42,43]. DEPDC1 has been identified in various cancers, including HCC, breast cancer, and prostate cancer, among others and is positively involved with multiple tumorous biological processes, including proliferation, invasion, and angiogenesis by activating different signaling pathways, such as CCL20/CCR6, E2F et al [44][45][46].…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic Biomarkers and Correlation with Immune Infiltrates in Hepatocellular Carcinoma Based on a Competing Endogenous RNA Network

Zhu

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Recently, competing endogenous RNAs (ceRNA) have revealed a significant role in the progression of HCC. Herein, we aimed to construct a ceRNA network to identify potential biomarkers and illustrate its correlation with immune infiltration in HCC. Methods: RNA sequencing data and clinical traits of HCC patients were downloaded from TCGA. The limma R package was used to identify differentially expressed (DE) RNAs. The predicted prognostic model was established using univariate and multivariate Cox regression. A K-M curve and GEPIA website were utilized for survival analysis. Functional annotation was determined using Enrichr and Reactome. Protein-to-protein network analysis was implemented using SRTNG and Cytoscape. Hub gene expression was validated by Oncomine and the Hunan Protein Atlas database. Immune infiltration was analyzed by TIMMER, and Drugbank was exploited to identify bioactive compounds. Results: The predicted model that was established revealed significant efficacy with 3- and 5-years of the area under ROC at 0.804 and 0.744, respectively. Eleven DEmiRNAs were screened out by a K-M survival analysis. Then, we constructed a ceRNA network, including 56 DElncRNAs, 6 DEmiRNAs, and 28 DEmRNAs. The 28 DEmRNAs were enriched in cancer-related pathways, for example, the TNF signaling pathway. Moreover, six hub genes, CEP55, DEPDC1, KIF23, CLSPN, MYBL2, and RACGAP1, were all overexpressed in HCC tissues and independently correlated with survival rate. Furthermore, expression of hub genes was related to immune cell infiltration in HCC, including B cells, CD8 + T cells, CD4 + T cells, monocytes, macrophages, neutrophils, and dendritic cells. Conclusions: The findings from this study demonstrate that CEP55, DEPDC1, KIF23, CLSPN, MYBL2, and RACGAP1 are closely associated with prognosis and immune infiltration, representing potential therapeutic targets or prognostic biomarkers in HCC.

show abstract

“…Exploring the differences in the molecular mechanisms of CEP55 in LUAD and LUSC is beneficial to further explore the new NSCLC targeted diagnostic approach, which is helpful for the effectiveness of anticancer therapy, thereby improving the overall survival rate of lung adenocarcinoma of lung cancer. Several studies have found that CEP55 is involved in the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway by triggering Akt phosphorylation [23][24][25]. According to reports in the literature, CEP55 binds and interacts with PI3KCA (p110), which may activate AktS473 to promote transcription of downstream target genes [19].…”

Section: Plos Onementioning

confidence: 99%

The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC

Wei

Wang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Objective To investigate the value of CEP55 as a diagnostic marker and independent prognostic factor in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), and to analyze its co-expression genes and related signaling pathways. Methods TCGA database and GEO database were used to analyze the expression of CEP55 in LUAD and LUSC compared with normal tissues. The co-expression genes of CEP55 in LUAD and LUSC were excavated by cBioPortal and enriched by KEGG and GO. Establishing Receiver operating characteristic (ROC) curve to evaluate the value of CEP55 as a diagnostic and prognostic factor. The association between CEP55 expression and the clinicopathological features was evaluated using χ2 tests. ROC curves for diagnosis and prognosis detection were constructed. Prognostic values were analyzed by univariate and multivariate Cox regression models. Results Compared with normal lung tissues, CEP55 expression was significantly upregulated in both LUAD and LUSC. ROC curve analysis showed that CEP55 could be used as an effective diagnostic target for LUAD (AUC = 0.969) and LUSC (AUC = 0.994). When CEP55 gene was selected as an independent prognostic factor, high expression of CEP55 was more disadvantageous to OS and RFS of LUAD patients (P<0.05), but no significant difference was found in LUSC patients (P>0.05). The number of co-expression genes of CEP55 in LUAD is more than that in LUSC, and is related to cell cycle, DNA replication and P53 signaling pathway.

show abstract

CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma

Cited by 27 publications

References 33 publications

Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer

Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer

Identification of Prognostic Biomarkers and Correlation with Immune Infiltrates in Hepatocellular Carcinoma Based on a Competing Endogenous RNA Network

The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC

Contact Info

Product

Resources

About